US5082767A
(en)
|
1989-02-27 |
1992-01-21 |
Hatfield G Wesley |
Codon pair utilization
|
US6140496A
(en)
|
1990-10-09 |
2000-10-31 |
Benner; Steven Albert |
Precursors for deoxyribonucleotides containing non-standard nucleosides
|
US5891680A
(en)
|
1995-02-08 |
1999-04-06 |
Whitehead Institute For Biomedical Research |
Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
US5922685A
(en)
|
1996-06-05 |
1999-07-13 |
Powderject Vaccines, Inc. |
IL-12 gene therapy of tumors
|
CA2268276A1
(en)
|
1996-10-18 |
1998-04-30 |
Jeff Nordstrom |
Gene expression and delivery systems and uses
|
US5994104A
(en)
|
1996-11-08 |
1999-11-30 |
Royal Free Hospital School Of Medicine |
Interleukin-12 fusion protein
|
CA2309535A1
(en)
|
1997-11-12 |
1999-05-20 |
Brigham And Women's Hospital, Inc. |
The translation enhancer element of the human amyloid precursor protein gene
|
CA2641217A1
(en)
|
1997-11-20 |
1999-06-03 |
Vical Incorporated |
Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
|
KR100519895B1
(ko)
|
1998-04-23 |
2005-10-13 |
다카라 바이오 가부시키가이샤 |
Dna 의 합성방법
|
AU761520B2
(en)
|
1998-09-15 |
2003-06-05 |
Genetics Institute, Llc |
Treatment of Kaposi's Sarcoma with IL-12
|
WO2000018778A1
(en)
|
1998-09-29 |
2000-04-06 |
Phylos, Inc. |
Synthesis of codon randomized nucleic acids
|
NZ517202A
(en)
|
1999-08-24 |
2004-05-28 |
Medarex Inc |
Human CTLA-4 antibodies and their uses
|
AU4050801A
(en)
|
2000-01-20 |
2001-07-31 |
Unitectra Inc. |
Intra-tumoral administration of il-12 encoding nucleic acid molecules
|
AU3120601A
(en)
|
2000-01-28 |
2001-08-07 |
Scripps Research Inst |
Methods of identifying synthetic transcriptional and translational regulatory elements, and compositions relating to same
|
US7468275B2
(en)
|
2000-01-28 |
2008-12-23 |
The Scripps Research Institute |
Synthetic internal ribosome entry sites and methods of identifying same
|
ES2164011B1
(es)
|
2000-02-25 |
2003-05-16 |
Inst Cientifico Tecnol Navarra |
Uso combinado de la quimiocina ip-10 y la interleucina-12 en la preparacion de composiciones para el tratamiento de tumores malignos.
|
EP1268759B1
(en)
|
2000-03-15 |
2006-09-27 |
Genexine Co., Ltd. |
Genes of il-12p40 subunit mutated for improving the activity of il-12 and use thereof for dna vaccine adjuvant
|
KR20020010206A
(ko)
|
2000-07-27 |
2002-02-04 |
이시우 |
인터루킨 12와 보조활성인자 b7.1 유전자를 함유하는dna 벡터 및 이벡터가 도입된 항암 세포백신
|
EP2842964A1
(de)
|
2001-06-05 |
2015-03-04 |
Curevac GmbH |
Virtuelles Verfahren zur Ermittlung einer modifzierten mRNA-Sequenz
|
WO2003004685A2
(en)
|
2001-07-03 |
2003-01-16 |
University Of Utah Research Foundation |
Soluble steroidal peptides for nucleic acid delivery
|
EP2390329B1
(en)
|
2001-09-28 |
2018-04-18 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
MicroRNA molecules
|
ATE427992T1
(de)
|
2001-11-14 |
2009-04-15 |
Toyo Boseki |
Dna-synthesepromotoren, mit dna-polymerase assoziierte faktoren und nutzung davon
|
CA2409775C
(en)
|
2001-12-03 |
2010-07-13 |
F. Hoffmann-La Roche Ag |
Reversibly modified thermostable enzymes for dna synthesis and amplification in vitro
|
AU2003228440B2
(en)
|
2002-04-01 |
2008-10-02 |
Walter Reed Army Institute Of Research |
Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell
|
US7595303B1
(en)
|
2002-09-05 |
2009-09-29 |
University Of South Florida |
Genetic adjuvants for immunotherapy
|
DE10248141B4
(de)
|
2002-10-11 |
2007-04-19 |
Universitätsklinikum Hamburg-Eppendorf |
Nukleinsäuren und deren Verwendung für die Gentherapie
|
DE10260805A1
(de)
|
2002-12-23 |
2004-07-22 |
Geneart Gmbh |
Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins
|
CA3031833C
(en)
|
2003-05-30 |
2022-07-26 |
University Of South Florida |
Uses of il-2 as a therapeutic medicament in combination with electroporation for the treatment of malignancies
|
EP1648914A4
(en)
|
2003-07-31 |
2009-12-16 |
Regulus Therapeutics Inc |
OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA
|
GB0329146D0
(en)
|
2003-12-16 |
2004-01-21 |
Glaxosmithkline Biolog Sa |
Vaccine
|
DE102004042546A1
(de)
|
2004-09-02 |
2006-03-09 |
Curevac Gmbh |
Kombinationstherapie zur Immunstimulation
|
EP1640018A1
(en)
|
2004-09-24 |
2006-03-29 |
Universität Zürich |
Combinational therapy for treating cancer
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
US7550264B2
(en)
|
2005-06-10 |
2009-06-23 |
Datascope Investment Corporation |
Methods and kits for sense RNA synthesis
|
KR20080025181A
(ko)
|
2005-06-30 |
2008-03-19 |
아케믹스 코포레이션 |
완전 2'-변형된 핵산 전사체를 생성하기 위한 물질 및 방법
|
US8101385B2
(en)
|
2005-06-30 |
2012-01-24 |
Archemix Corp. |
Materials and methods for the generation of transcripts comprising modified nucleotides
|
WO2007005874A2
(en)
|
2005-07-01 |
2007-01-11 |
Medarex, Inc. |
Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
|
HUE043492T2
(hu)
|
2005-08-23 |
2019-08-28 |
Univ Pennsylvania |
Módosított nukleozidokat tartalmazó RNS és eljárások az alkalmazására
|
US9012219B2
(en)
|
2005-08-23 |
2015-04-21 |
The Trustees Of The University Of Pennsylvania |
RNA preparations comprising purified modified RNA for reprogramming cells
|
JP5225087B2
(ja)
|
2005-08-24 |
2013-07-03 |
ザ スクリプス リサーチ インスティチュート |
翻訳エンハンサーエレメント依存性のベクター系
|
DE102005046490A1
(de)
|
2005-09-28 |
2007-03-29 |
Johannes-Gutenberg-Universität Mainz |
Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
|
EA015338B1
(ru)
|
2005-12-30 |
2011-06-30 |
Мерк Патент Гмбх |
ВАРИАНТЫ ИЛ-12p40 С УЛУЧШЕННОЙ СТАБИЛЬНОСТЬЮ
|
EP2586455B1
(en)
|
2006-01-05 |
2014-06-25 |
The Ohio State University Research Foundation |
MicroRNA expressions abnormalities in pancreatic endocrine and acinar tumors
|
EP2487252B1
(en)
|
2006-01-05 |
2014-10-15 |
The Ohio State University Research Foundation |
MicroRNA-based methods for the diagnosis of colon cancer
|
WO2007084364A2
(en)
|
2006-01-13 |
2007-07-26 |
The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health |
Improved il-12 for expression in mammalian cells
|
KR101241477B1
(ko)
|
2006-01-27 |
2013-03-08 |
엘지이노텍 주식회사 |
질화물 반도체 발광소자 및 그 제조 방법
|
EP2522746B1
(en)
|
2006-03-02 |
2014-11-12 |
The Ohio State University Research Foundation |
MicroRNA expression profile associated with pancreatic cancer
|
US7919079B2
(en)
|
2006-03-31 |
2011-04-05 |
Biosante Pharmaceuticals, Inc. |
Cancer immunotherapy compositions and methods of use
|
EP2007423A2
(en)
|
2006-04-05 |
2008-12-31 |
Pfizer Products Incorporated |
Ctla4 antibody combination therapy
|
US20080046192A1
(en)
|
2006-08-16 |
2008-02-21 |
Richard Lathrop |
Polypepetide-encoding nucleotide sequences with refined translational kinetics and methods of making same
|
EP2487240B1
(en)
|
2006-09-19 |
2016-11-16 |
Interpace Diagnostics, LLC |
Micrornas differentially expressed in pancreatic diseases and uses thereof
|
DE102006051516A1
(de)
|
2006-10-31 |
2008-05-08 |
Curevac Gmbh |
(Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
|
ES2425416T3
(es)
|
2006-11-01 |
2013-10-15 |
The Ohio State University Research Foundation |
Firma de expresión del microARN para predecir la supervivencia y la metástasis en el carcinoma hepatocelular
|
US20090092974A1
(en)
|
2006-12-08 |
2009-04-09 |
Asuragen, Inc. |
Micrornas differentially expressed in leukemia and uses thereof
|
EP2207891B1
(en)
|
2006-12-22 |
2012-07-25 |
Archemix LLC |
Materials and methods for the generation of transcripts comprising modified nucleotides
|
US8765462B2
(en)
|
2007-05-04 |
2014-07-01 |
University Health Network |
IL-12 immunotherapy for cancer
|
WO2008147974A1
(en)
|
2007-05-23 |
2008-12-04 |
University Of South Florida |
Micro-rnas modulating immunity and inflammation
|
US20090099034A1
(en)
|
2007-06-07 |
2009-04-16 |
Wisconsin Alumni Research Foundation |
Reagents and Methods for miRNA Expression Analysis and Identification of Cancer Biomarkers
|
ES2616355T3
(es)
|
2007-06-18 |
2017-06-12 |
Merck Sharp & Dohme B.V. |
Anticuerpos para el receptor humano de muerte programada PD-1
|
US20090028857A1
(en)
|
2007-07-23 |
2009-01-29 |
Cell Genesys, Inc. |
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
|
TWI359030B
(en)
|
2007-08-24 |
2012-03-01 |
Univ Nat Taiwan |
Treatment of cellular proliferative disorders
|
ES2573458T3
(es)
|
2007-09-14 |
2016-06-08 |
Vrije Universiteit Brussel |
Mejoramiento de la capacidad estimulatoria de las células T de las células que presentan antígeno humano y su uso en vacunación
|
US20110086904A1
(en)
|
2007-09-17 |
2011-04-14 |
The Trustees Of The University Of Pennsylvania |
GENERATION OF HYPERSTABLE mRNAs
|
EP2399610A3
(en)
*
|
2007-09-24 |
2012-09-05 |
Bar-Ilan University |
Polymer nanoparticles coated by magnetic metal oxide and uses thereof
|
RU2524431C2
(ru)
|
2007-09-26 |
2014-07-27 |
Интрексон Корпорейшн |
Синтетические 5 utr (нетранслируемые области), экспрессионные векторы и способ повышения трансгенной экспрессии
|
AU2008329755A1
(en)
|
2007-11-30 |
2009-06-04 |
The Ohio State University Research Foundation |
MicroRNA expression profiling and targeting in peripheral blood in lung cancer
|
SG10201408164XA
(en)
|
2007-12-11 |
2015-01-29 |
Scripps Research Inst |
Compositions and methods related to mrna translational enhancer elements
|
EP2072618A1
(en)
|
2007-12-14 |
2009-06-24 |
Johannes Gutenberg-Universität Mainz |
Use of RNA for reprogramming somatic cells
|
WO2009086558A1
(en)
*
|
2008-01-02 |
2009-07-09 |
Tekmira Pharmaceuticals Corporation |
Improved compositions and methods for the delivery of nucleic acids
|
EP2260110B1
(en)
|
2008-02-08 |
2014-11-12 |
Asuragen, INC. |
miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
|
CN102015027A
(zh)
|
2008-02-28 |
2011-04-13 |
俄亥俄州立大学研究基金会 |
与人慢性淋巴细胞性白血病(ccl)相关的微rna特征和其用途
|
EP2279254B1
(en)
*
|
2008-04-15 |
2017-07-05 |
Protiva Biotherapeutics Inc. |
Novel lipid formulations for nucleic acid delivery
|
EP2112235A1
(en)
|
2008-04-24 |
2009-10-28 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Compositions and methods for microRNA expression profiling of nasopharyngeal carcinoma
|
WO2009140206A1
(en)
|
2008-05-11 |
2009-11-19 |
The Gov. Of The U. S. A., As Represented By The Secretary Of The Dept. Of Health And Human Services |
Improved expression of il-12 family heterodimers
|
US8126653B2
(en)
|
2008-07-31 |
2012-02-28 |
Dna Twopointo, Inc. |
Synthetic nucleic acids for expression of encoded proteins
|
US7561973B1
(en)
|
2008-07-31 |
2009-07-14 |
Dna Twopointo, Inc. |
Methods for determining properties that affect an expression property value of polynucleotides in an expression system
|
US8401798B2
(en)
|
2008-06-06 |
2013-03-19 |
Dna Twopointo, Inc. |
Systems and methods for constructing frequency lookup tables for expression systems
|
PL215513B1
(pl)
|
2008-06-06 |
2013-12-31 |
Univ Warszawski |
Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
|
WO2009149539A1
(en)
|
2008-06-10 |
2009-12-17 |
Université de Montréal |
Enhancing antigen-specific cd8+ t cell response using irf-7 mrna
|
WO2010018563A2
(en)
|
2008-08-12 |
2010-02-18 |
Rosetta Genomics Ltd. |
Compositions and methods for the prognosis of lymphoma
|
PE20110435A1
(es)
|
2008-08-25 |
2011-07-20 |
Amplimmune Inc |
Composiciones antagonistas del pd-1
|
CN102439169B
(zh)
|
2008-11-13 |
2014-11-19 |
复旦大学 |
用于结肠直肠癌的微rna表达谱分析的组合物和方法
|
PT4209510T
(pt)
|
2008-12-09 |
2024-04-02 |
Hoffmann La Roche |
Anticorpos anti-pm-l1 e a sua utilização para a melhoria do funcionamento das células t
|
EP2358902A1
(en)
|
2008-12-10 |
2011-08-24 |
Universität Regensburg |
Compositions and methods for micro-rna expression profiling of cancer stem cells
|
WO2010126766A1
(en)
*
|
2009-04-30 |
2010-11-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Inducible interleukin-12
|
US20120264626A1
(en)
|
2009-05-08 |
2012-10-18 |
The Ohio State University Research Foundation |
MicroRNA Expression Profiling and Targeting in Chronic Obstructive Pulmonary Disease (COPD) Lung Tissue and Methods of Use Thereof
|
ES2901627T3
(es)
|
2009-06-10 |
2022-03-23 |
Arbutus Biopharma Corp |
Formulación lipídica mejorada
|
ES2587963T3
(es)
|
2009-07-31 |
2016-10-27 |
Ethris Gmbh |
ARN con una combinación de nucleótidos no modificados y modificados para la expresión de proteínas
|
EP2281579A1
(en)
|
2009-08-05 |
2011-02-09 |
BioNTech AG |
Vaccine composition comprising 5'-Cap modified RNA
|
US20110082055A1
(en)
|
2009-09-18 |
2011-04-07 |
Codexis, Inc. |
Reduced codon mutagenesis
|
WO2011066342A2
(en)
|
2009-11-24 |
2011-06-03 |
Amplimmune, Inc. |
Simultaneous inhibition of pd-l1/pd-l2
|
ME03091B
(me)
|
2009-12-01 |
2019-01-20 |
Translate Bio Inc |
Isporuka irnk za povećanje ekspresije proteina i enzima u humanim genetskim oboljenjima
|
WO2011076143A1
(en)
|
2009-12-24 |
2011-06-30 |
Fudan University |
Compositions and methods for microrna expression profiling of lung cancer
|
WO2011076142A1
(en)
|
2009-12-24 |
2011-06-30 |
Fudan University |
Compositions and methods for microrna expession profiling in plasma of colorectal cancer
|
EP2341145A1
(en)
|
2009-12-30 |
2011-07-06 |
febit holding GmbH |
miRNA fingerprint in the diagnosis of diseases
|
WO2011094683A2
(en)
|
2010-01-29 |
2011-08-04 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Method of identifying myelodysplastic syndromes
|
EP2354246A1
(en)
|
2010-02-05 |
2011-08-10 |
febit holding GmbH |
miRNA in the diagnosis of ovarian cancer
|
WO2011113030A2
(en)
|
2010-03-11 |
2011-09-15 |
H.Lee Moffitt Cancer Center & Research Institute |
Human cancer micro-rna expression profiles predictive of chemo-response
|
WO2011157294A1
(en)
|
2010-06-16 |
2011-12-22 |
Universita' Degli Studi Di Padova |
Compositions for use in treating or preventing cancer, breast cancer, lung cancer, ovarian cancer, metastasis, heart failure, cardiac remodelling, dilated cardiomyopathy, autoimmune diseases, or diseases or disorders related thereto
|
WO2012009644A2
(en)
|
2010-07-16 |
2012-01-19 |
Arizona Board Of Regents |
Methods to identify synthetic and natural rna elements that enhance protein translation
|
WO2012038448A1
(en)
|
2010-09-21 |
2012-03-29 |
Riboxx Gmbh |
Method for synthesizing rna using dna template
|
WO2012072096A1
(en)
|
2010-12-03 |
2012-06-07 |
Biontech Ag |
Method for cellular rna expression
|
KR20120066952A
(ko)
|
2010-12-15 |
2012-06-25 |
주식회사 롤팩 |
7층 구조의 공압출 항균 진공포장 필름 및 그 제조방법
|
EP2651445A2
(en)
|
2010-12-16 |
2013-10-23 |
SPRNA GmbH |
Pharmaceutical composition consisting of rna having alkali metal as counter ion and formulated with dications
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
WO2012122444A1
(en)
|
2011-03-10 |
2012-09-13 |
Provectus Pharmaceuticals, Inc. |
Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
|
CA2831613A1
(en)
*
|
2011-03-31 |
2012-10-04 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
US20140113978A1
(en)
|
2011-05-01 |
2014-04-24 |
University Of Rochester |
Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof
|
EP2706690B1
(en)
|
2011-05-02 |
2018-03-21 |
LG Electronics Inc. |
Method for transmitting/receiving data in wireless access system and base station for same
|
EP2944961A1
(en)
|
2011-05-06 |
2015-11-18 |
XenTech |
Markers for cancer prognosis and therapy and methods of use
|
BR112013031553A2
(pt)
|
2011-06-08 |
2020-11-10 |
Shire Human Genetic Therapies, Inc. |
composições, mrna que codifica para uma hgla e seu uso, uso de pelo menos uma molécula de mrna e um veículo de transferência e uso de um mrna que codifica para proteína exógena
|
DK2732052T3
(en)
|
2011-07-15 |
2017-02-20 |
Leo Pharma As |
Diagnostic microRNA profiling in cutaneous T cell lymphoma (CTCL)
|
US20150080243A1
(en)
|
2011-09-01 |
2015-03-19 |
Allegro Diagnostics Corp. |
Methods and compositions for detecting cancer based on mirna expression profiles
|
WO2013039857A1
(en)
|
2011-09-12 |
2013-03-21 |
modeRNA Therapeutics |
Engineered nucleic acids and methods of use thereof
|
EP4015005A1
(en)
|
2011-10-03 |
2022-06-22 |
ModernaTX, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
US20150017121A1
(en)
|
2011-10-11 |
2015-01-15 |
Universitat Zurich |
Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy
|
WO2013066678A1
(en)
|
2011-10-26 |
2013-05-10 |
Georgetown University |
Microrna expression profiling of thyroid cancer
|
EP3763741A1
(en)
|
2011-11-28 |
2021-01-13 |
Merck Patent GmbH |
Anti-pd-l1 antibodies and uses thereof
|
JP6333730B2
(ja)
|
2011-12-12 |
2018-05-30 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
改善されたil−12遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法
|
EP2623121A1
(en)
|
2012-01-31 |
2013-08-07 |
Bayer Innovation GmbH |
Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
|
WO2013143555A1
(en)
|
2012-03-26 |
2013-10-03 |
Biontech Ag |
Rna formulation for immunotherapy
|
AU2013243955B2
(en)
|
2012-04-02 |
2018-02-22 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
WO2013173223A1
(en)
|
2012-05-15 |
2013-11-21 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
EP2672197A1
(de)
|
2012-06-06 |
2013-12-11 |
Hörmann Energietechnik GmbH & Co. KG |
Montageanordnung zur dachseitigen Montage von Flächenkörpern an einem Bauwerk
|
EP2859102A4
(en)
|
2012-06-08 |
2016-05-11 |
Shire Human Genetic Therapies |
NUCLEASE RESISTANT POLYNUCLEOTIDES AND USES THEREOF
|
EP3884949A1
(en)
|
2012-06-08 |
2021-09-29 |
Translate Bio, Inc. |
Pulmonary delivery of mrna to non-lung target cells
|
US20140020675A1
(en)
|
2012-07-18 |
2014-01-23 |
Chandrashekhar Sonwane |
Solar receiver
|
WO2014028429A2
(en)
|
2012-08-14 |
2014-02-20 |
Moderna Therapeutics, Inc. |
Enzymes and polymerases for the synthesis of rna
|
CN102876684B
(zh)
*
|
2012-09-17 |
2014-10-08 |
青岛康立泰药业有限公司 |
人白细胞介素-12的编码基因、真核宿主细胞和表达方法
|
US20150307542A1
(en)
|
2012-10-03 |
2015-10-29 |
Moderna Therapeutics, Inc. |
Modified nucleic acid molecules and uses thereof
|
WO2014071963A1
(en)
|
2012-11-09 |
2014-05-15 |
Biontech Ag |
Method for cellular rna expression
|
PT2922554T
(pt)
*
|
2012-11-26 |
2022-06-28 |
Modernatx Inc |
Arn modificado nas porções terminais
|
EP2929035A1
(en)
*
|
2012-12-07 |
2015-10-14 |
Shire Human Genetic Therapies, Inc. |
Lipidic nanoparticles for mrna delivering
|
JP2016504050A
(ja)
|
2013-01-17 |
2016-02-12 |
モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. |
細胞表現型の改変のためのシグナルセンサーポリヌクレオチド
|
WO2014127917A1
(en)
|
2013-02-22 |
2014-08-28 |
Curevac Gmbh |
Combination of vaccination and inhibition of the pd-1 pathway
|
JP6352950B2
(ja)
|
2013-03-08 |
2018-07-04 |
ノバルティス アーゲー |
活性薬物の送達のための脂質と脂質組成物
|
WO2014164253A1
(en)
|
2013-03-09 |
2014-10-09 |
Moderna Therapeutics, Inc. |
Heterologous untranslated regions for mrna
|
CN105142676B
(zh)
|
2013-03-14 |
2022-06-28 |
夏尔人类遗传性治疗公司 |
Cftr mrna组合物以及相关方法和用途
|
AU2014239250A1
(en)
|
2013-03-14 |
2015-08-27 |
Shire Human Genetic Therapies, Inc. |
Quantitative assessment for cap efficiency of messenger RNA
|
MX2015011945A
(es)
|
2013-03-14 |
2015-12-01 |
Shire Human Genetic Therapies |
Evaluacion cuantitativa para la eficacia de los casquetes de arn mensajero.
|
EP3467108B1
(en)
|
2013-03-14 |
2024-05-22 |
Translate Bio, Inc. |
Methods for purification of messenger rna
|
JP6399560B2
(ja)
|
2013-03-14 |
2018-10-03 |
トランスレイト バイオ, インコーポレイテッド |
mRNAによってコードされる抗体を送達するための方法及び組成物
|
MX2015011943A
(es)
|
2013-03-14 |
2015-12-01 |
Shire Human Genetic Therapies |
Acidos ribonucleicos con nucleotidos modificados por 4'-tio y metodos relacionados.
|
EP2970940B1
(en)
|
2013-03-14 |
2018-07-25 |
Translate Bio, Inc. |
Mrna therapeutic compositions and use to treat diseases and disorders
|
HUE039189T2
(hu)
|
2013-03-15 |
2018-12-28 |
Translate Bio Inc |
Nukleinsavak bejuttatásának szinergista fokozása kevert kiszerelésekkel
|
WO2015024667A1
(en)
|
2013-08-21 |
2015-02-26 |
Curevac Gmbh |
Method for increasing expression of rna-encoded proteins
|
PL3044234T3
(pl)
|
2013-09-13 |
2020-10-19 |
Beigene Switzerland Gmbh |
Przeciwciała anty-PD1 i ich zastosowanie jako środków terapeutycznych i diagnostycznych
|
JP6558699B2
(ja)
|
2013-10-01 |
2019-08-14 |
国立大学法人三重大学 |
抗原提示を促進するエピトープ間配列を含むt細胞誘導ワクチン
|
AU2014337156A1
(en)
|
2013-10-18 |
2016-05-12 |
Modernatx, Inc. |
Compositions and methods for tolerizing cellular systems
|
ES2865699T3
(es)
|
2013-10-22 |
2021-10-15 |
Translate Bio Inc |
Formulaciones de lípidos para la administración de ARN mensajero
|
WO2015061491A1
(en)
|
2013-10-22 |
2015-04-30 |
Shire Human Genetic Therapies, Inc. |
Mrna therapy for phenylketonuria
|
WO2015062738A1
(en)
|
2013-11-01 |
2015-05-07 |
Curevac Gmbh |
Modified rna with decreased immunostimulatory properties
|
US20150190506A1
(en)
*
|
2013-12-17 |
2015-07-09 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
US20160311879A1
(en)
*
|
2013-12-18 |
2016-10-27 |
Intrexon Corporation |
Single chain il-12 nucleic acids, polypeptides, and uses thereof
|
CA2927254C
(en)
|
2013-12-30 |
2023-10-24 |
Curevac Ag |
Artificial nucleic acid molecules
|
AU2014375402B2
(en)
|
2013-12-30 |
2020-10-01 |
CureVac SE |
Artificial nucleic acid molecules
|
SG10201912038TA
(en)
*
|
2014-04-23 |
2020-02-27 |
Modernatx Inc |
Nucleic acid vaccines
|
RS63848B1
(sr)
*
|
2014-06-25 |
2023-01-31 |
Acuitas Therapeutics Inc |
Novi lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina
|
WO2016048903A1
(en)
|
2014-09-22 |
2016-03-31 |
Intrexon Corporation |
Improved therapeutic control of heterodimeric and single chain forms of interleukin-12
|
CA3012602A1
(en)
|
2015-01-30 |
2016-08-04 |
President And Fellows Of Harvard College |
Peritumoral and intratumoral materials for cancer therapy
|
EP3326641B1
(en)
|
2015-04-22 |
2019-06-26 |
CureVac AG |
Rna containing composition for treatment of tumor diseases
|
US10682401B2
(en)
|
2015-05-19 |
2020-06-16 |
Morphogenesis, Inc. |
Multi-indication mRNA cancer immunotherapy
|
US9636388B2
(en)
|
2015-05-19 |
2017-05-02 |
Morphogenesis, Inc. |
Multi-indication mRNA cancer immunotherapy
|
CA2998810A1
(en)
*
|
2015-09-17 |
2017-03-23 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
EP3205356A1
(en)
|
2016-02-10 |
2017-08-16 |
Onkoloski Institut Ljubljana |
Plasmid expression vector encoding human interleukin 12 under transcriptional control of p21 promoter and without antibiotic resistance for cancer gene therapy and other uses thereof
|
EP3211000B1
(en)
|
2016-02-25 |
2019-01-30 |
Provecs Medical GmbH |
Novel immunostimulating vector system
|
LT3458083T
(lt)
|
2016-05-18 |
2023-02-10 |
Modernatx, Inc. |
Polinukleotidai, koduojantys interleukiną-12 (il12), ir jų naudojimas
|
WO2018033254A2
(en)
|
2016-08-19 |
2018-02-22 |
Curevac Ag |
Rna for cancer therapy
|
JP2019532648A
(ja)
|
2016-10-07 |
2019-11-14 |
ボード オブ リージェンツ ザ ユニヴァーシティ オブ テキサス システム |
がんの治療のための膜係留il−12を発現しているt細胞
|